GJB6抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10905(GJB6 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

GJB6 antibody targets the gap junction protein beta-6 (GJB6), also known as connexin 30 (Cx30), which is encoded by the *GJB6* gene. Gap junction proteins form intercellular channels facilitating direct communication between adjacent cells, enabling the exchange of ions, metabolites, and signaling molecules. These channels are critical for maintaining tissue homeostasis, particularly in organs like the skin, inner ear, and brain.

Mutations in *GJB6* are linked to several disorders. Notably, autosomal-dominant mutations cause hidrotic ectodermal dysplasia (Clouston syndrome), characterized by hair loss, nail dystrophy, and hyperkeratosis. Recessive mutations in *GJB6*, often in combination with *GJB2* (connexin 26), are associated with nonsyndromic hearing loss. GJB6 antibodies are thus valuable tools for studying these conditions, aiding in protein localization, expression analysis, and understanding pathogenic mechanisms.

In research, GJB6 antibodies are used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to assess protein distribution in tissues such as the epidermis, cochlea, and placenta. They also help investigate the role of Cx30 in skin barrier function, cochlear potassium recycling, and neural activity. Clinically, these antibodies may assist in diagnosing genetic disorders or validating gene therapy outcomes. However, specificity and cross-reactivity with other connexins require careful validation. Overall, GJB6 antibodies contribute to both basic research and translational studies of connexin-related diseases.